2023-508054-25-01CompletedPhase 1
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 5 Mar 2024
- Start date
- 26 Feb 2025
- Lead sponsor
- Nanexa AB
- Diseases
- Type 2 diabetes
- EU CT number
- 2023-508054-25-01
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.